Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 02 Jun 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Oct 2021 Planned End Date changed from 1 Apr 2024 to 1 Jul 2024.
- 21 Oct 2021 Planned primary completion date changed from 1 Apr 2024 to 1 Jul 2024.